FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
NAVNETEDUL
76
-1.7 (-2.19%)
Updated 03:28 10/07 IST
NAVNETEDUL Buy or Sell - FrontPage Forums
0 Users have submitted 0 trade ideas of Rs. 0 for NAVNETEDUL
Disclaimer0% Bullish
0% Bearish
NAVNETEDUL Buy or Sell - Brokerage Reports
No. of reports in last year
6
No. of analysts
2
Average Consensus Forecast
111.67
Consensus Potential
27.62%
NAVNETEDUL Ratings
Long term NAVNETEDUL rating by FrontPage users
- ★★
- ★★
- ★★
- ★★
- ★★
5/5 (2 Ratings)
Find answers to all your questions on live NAVNETEDUL message board: Is NAVNETEDUL buy or sell? Should I buy NAVNETEDUL shares? Why are NAVNETEDUL shares falling? Should I invest in NAVNETEDUL stock?
- Home
- NAVNETEDUL Forum
NAVNETEDUL Share Price Discussion
N
Reputation: 3,973 • Jul 9 7:13 AM
Top stocks to bet on: ICICI Bank, Biocon, Rallis India can return 15-20% in near term
On the upside, the Nifty needs to sustain 10,800 for the uptrend to continue towards 11,100 and then possibly 11,350.
On the upside, the Nifty needs to sustain 10,800 for the uptrend to continue towards 11,100 and then possibly 11,350.
Moneycontrol
Like
Reply
N
Reputation: 3,973 • Jul 7 12:43 PM
Hot Stocks | Natco Pharma, NCC, Century Textiles three short-term buy calls
On the weekly chart, Nifty has formed a bullish higher top higher bottom pattern. A similar pattern is also observed in the Midcap and Smallcap indices, indicating broad-based rally in the markets.
On the weekly chart, Nifty has formed a bullish higher top higher bottom pattern. A similar pattern is also observed in the Midcap and Smallcap indices, indicating broad-based rally in the markets.
Moneycontrol
Like
Reply
N
Reputation: 3,973 • Jun 19 5:18 AM
Buy Natco Pharma; target of Rs 740: ICICI Direct
ICICI Direct is bullish on Natco Pharma has recommended buy rating on the stock with a target price of Rs 740 in its research report dated June 19, 2020.
ICICI Direct is bullish on Natco Pharma has recommended buy rating on the stock with a target price of Rs 740 in its research report dated June 19, 2020.
Moneycontrol
Like
Reply
N
Reputation: 3,973 • Jun 19 3:48 AM
Buy Navneet Education; target of Rs 95: ICICI Direct
ICICI Direct is bullish on Navneet Education has recommended buy rating on the stock with a target price of Rs 95 in its research report dated June 15, 2020.
ICICI Direct is bullish on Navneet Education has recommended buy rating on the stock with a target price of Rs 95 in its research report dated June 15, 2020.
Moneycontrol
Like
Reply
N
Reputation: 3,973 • Jun 19 3:33 AM
Hold Navneet Education; target of Rs 89: Prabhudas Lilladher
Prabhudas Lilladher recommended Hold rating on Navneet Education with a target price of Rs 89 in its research report dated June 18, 2020.
Prabhudas Lilladher recommended Hold rating on Navneet Education with a target price of Rs 89 in its research report dated June 18, 2020.
Moneycontrol
Like
Reply
D
Reputation: 17,900 • Jun 19 3:00 AM
Prabhudas Lilladher target on NAVNETEDUL
Date: 18-Jun-20
Broker: Prabhudas Lilladher
Price @ Call: 80.01
Target: 89
Recommendation: ACCUMULATE
Like
Reply
N
Reputation: 3,973 • Jun 18 3:58 AM
Natco Pharma Standalone March 2020 Net Sales at Rs 420.10 crore, up 0.91% Y-o-Y
Moneycontrol
Like
Reply
N
Reputation: 3,973 • Jun 18 3:43 AM
Natco Pharma Consolidated March 2020 Net Sales at Rs 454.80 crore, down 0.2% Y-o-Y
Moneycontrol
Like
Reply
N
Reputation: 3,973 • Jun 17 8:03 AM
Natco Pharma's Q4 net profit falls 22%; shares drop 3%
Consolidated revenue declined marginally by 0.2 percent YoY to Rs 454.8 crore in Q4FY20 against Rs 455.7 crore in Q4FY19.
Consolidated revenue declined marginally by 0.2 percent YoY to Rs 454.8 crore in Q4FY20 against Rs 455.7 crore in Q4FY19.
Moneycontrol
Like
Reply
N
Reputation: 3,973 • May 19 8:38 AM
Coronavirus pandemic | Natco Pharma donates chloroquine tablets for global trials
The trial will examine whether the anti-malarial drug can protect essential healthcare workers from COVID-19 virus.
The trial will examine whether the anti-malarial drug can protect essential healthcare workers from COVID-19 virus.
Moneycontrol
Like
Reply
N
Reputation: 3,973 • Apr 28 6:18 AM
Natco Pharma gains on US FDA approval; share up 27% in a month
The share price up 27 percent in last 1-month.
The share price up 27 percent in last 1-month.
Moneycontrol
Like
Reply
D
Reputation: 17,900 • Apr 20 4:00 AM
Prabhudas Lilladher target on NAVNETEDUL
Date: 19-Apr-20
Broker: Prabhudas Lilladher
Price @ Call: 65.57
Target: 82
Recommendation: BUY
Like
Reply
N
Reputation: 3,973 • Mar 19 1:23 AM
Stocks in the news: VST Tillers Tractors, Karur Vysya Bank, Vakrangee, NTPC, Emami
VST Tillers Tractors | Karur Vysya Bank | Vakrangee | NTPC | Emami and NLC India are among the stocks that are in the news today.
VST Tillers Tractors | Karur Vysya Bank | Vakrangee | NTPC | Emami and NLC India are among the stocks that are in the news today.
Moneycontrol
Like
Reply
N
Reputation: 3,973 • Mar 18 1:48 AM
Trade Setup for Thursday: Top 15 things to know before Opening Bell
Key support level for Nifty is placed at 8208.05, followed by 7947.3. If the index moves up, key resistance levels to watch out for are 8928.55 and 9388.3.
Key support level for Nifty is placed at 8208.05, followed by 7947.3. If the index moves up, key resistance levels to watch out for are 8928.55 and 9388.3.
Moneycontrol
Like
Reply
N
Reputation: 3,973 • Feb 13 2:48 AM
Natco Pharma Consolidated December 2019 Net Sales at Rs 482.20 crore, down 13.38% Y-o-Y
Moneycontrol
Like
Reply
N
Reputation: 3,973 • Feb 12 12:13 PM
Natco Pharma Q3 net profit declines 34% to Rs 104.4cr
Consolidated total income stood at Rs 513 crore for the quarter under consideration. It was Rs 580 crore for the same period a year ago.
Consolidated total income stood at Rs 513 crore for the quarter under consideration. It was Rs 580 crore for the same period a year ago.
Moneycontrol
Like
Reply
D
Reputation: 17,900 • Feb 4 7:00 AM
ICICIdirect.com target on NAVNETEDUL
Date: 04-Feb-20
Broker: ICICIdirect.com
Price @ Call: 91.5
Target: 115
Recommendation: BUY
Like
Reply
D
Reputation: 17,900 • Feb 3 6:00 AM
Prabhudas Lilladher target on NAVNETEDUL
Date: 03-Feb-20
Broker: Prabhudas Lilladher
Price @ Call: 92.75
Target: 108
Recommendation: BUY
Like
Reply
N
Reputation: 3,973 • Feb 1 6:18 AM
Budget 2020: Rs 99,300 crore set aside for education sector; Navneet Education, NIIT in focus
Government to source more ECB & FDI for the education sector, says FM Nirmala Sitharaman.
Government to source more ECB & FDI for the education sector, says FM Nirmala Sitharaman.
Moneycontrol
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
- keyboard_arrow_down
NAVNETEDUL Share Price - Technicals
- NewsBotJun 19 3:48 AMBuy Navneet Education; target of Rs 95: ICICI DirectMoneycontrolNewsBotJun 19 3:33 AMHold Navneet Education; target of Rs 89: Prabhudas LilladherMoneycontrolNewsBotJun 18 3:58 AMNatco Pharma Standalone March 2020 Net Sales at Rs 420.10 crore, up 0.91% Y-o-YMoneycontrolNewsBotJun 18 3:43 AMNatco Pharma Consolidated March 2020 Net Sales at Rs 454.80 crore, down 0.2% Y-o-YMoneycontrolNewsBotApr 28 6:18 AMNatco Pharma gains on US FDA approval; share up 27% in a monthMoneycontrolNewsBotMar 19 1:23 AMStocks in the news: VST Tillers Tractors, Karur Vysya Bank, Vakrangee, NTPC, EmamiMoneycontrolNewsBotMar 18 1:48 AMTrade Setup for Thursday: Top 15 things to know before Opening BellMoneycontrolNewsBotFeb 13 2:48 AMNatco Pharma Consolidated December 2019 Net Sales at Rs 482.20 crore, down 13.38% Y-o-YMoneycontrolNewsBotFeb 12 12:13 PMNatco Pharma Q3 net profit declines 34% to Rs 104.4crMoneycontrolNewsBotFeb 1 6:18 AMBudget 2020: Rs 99,300 crore set aside for education sector; Navneet Education, NIIT in focusMoneycontrol
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.